| Byhalia Vision Center Llc | |
|
8250 Hwy 178 West, Byhalia, MS 38611-6776 | |
| (662) 850-1051 | |
| (662) 850-1053 |
| Full Name | Byhalia Vision Center Llc |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 8250 Hwy 178 West, Byhalia, Mississippi |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952965022 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (* (Not Available)) | Primary |
| Provider Name | Jonathan Wilson |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1881738532 PECOS PAC ID: 7315901592 Enrollment ID: I20080303000201 |
News Archive
China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic," or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), today announced that on September 2, 2009, the PRC's State Food and Drug Administration (the "SFDA") renewed SFDA certification of compliance with Good Manufacturing Practices ("GMP") for the production facility of Qianfeng Biological Products Co., Ltd. ("Qianfeng"), China Biologic's indirectly owned subsidiary.
The flu vaccine may not only ward off serious complications from influenza, it may also reduce the risk of heart attack or stroke by more than 50 per cent among those who have had a heart attack, according to new research led by Dr. Jacob Udell, a cardiologist at Women's College Hospital and clinician-scientist at the University of Toronto. What's more, the vaccine's heart protective effects may be even greater among those who receive a more potent vaccine.
Elusys Therapeutics, Inc., a privately-held biopharmaceutical company, announced today that it has been awarded a second contract year of funding valued at $40.6 million for the advanced development of Anthim for the prevention and treatment of anthrax infection following a biowarfare attack. This funding is in addition to $16.8 million already received under this contract and is part of a potential five year contract award totaling up to $143 million if all options are exercised by the Government.
A three-day conference exploring ways to increase access to family planning services in Africa kicked off in Nairobi, Kenya, on Tuesday, Capital FM reports. The meeting, which is hosted by USAID, will bring together "USAID's partners in sub-Saharan Africa who include Angola, Burundi, [Democratic Republic of Congo], Ethiopia, Guinea, Kenya, Nigeria, South Sudan and Tanzania," to work to identify gaps in reproductive and family planning services and address ways to reach out to populations in need, the news service writes (Karong'o, 5/11).
› Verified 9 days ago
| Provider Name | Michael E Obrien |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1306925029 PECOS PAC ID: 1153405030 Enrollment ID: I20080306000398 |
News Archive
China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic," or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), today announced that on September 2, 2009, the PRC's State Food and Drug Administration (the "SFDA") renewed SFDA certification of compliance with Good Manufacturing Practices ("GMP") for the production facility of Qianfeng Biological Products Co., Ltd. ("Qianfeng"), China Biologic's indirectly owned subsidiary.
The flu vaccine may not only ward off serious complications from influenza, it may also reduce the risk of heart attack or stroke by more than 50 per cent among those who have had a heart attack, according to new research led by Dr. Jacob Udell, a cardiologist at Women's College Hospital and clinician-scientist at the University of Toronto. What's more, the vaccine's heart protective effects may be even greater among those who receive a more potent vaccine.
Elusys Therapeutics, Inc., a privately-held biopharmaceutical company, announced today that it has been awarded a second contract year of funding valued at $40.6 million for the advanced development of Anthim for the prevention and treatment of anthrax infection following a biowarfare attack. This funding is in addition to $16.8 million already received under this contract and is part of a potential five year contract award totaling up to $143 million if all options are exercised by the Government.
A three-day conference exploring ways to increase access to family planning services in Africa kicked off in Nairobi, Kenya, on Tuesday, Capital FM reports. The meeting, which is hosted by USAID, will bring together "USAID's partners in sub-Saharan Africa who include Angola, Burundi, [Democratic Republic of Congo], Ethiopia, Guinea, Kenya, Nigeria, South Sudan and Tanzania," to work to identify gaps in reproductive and family planning services and address ways to reach out to populations in need, the news service writes (Karong'o, 5/11).
› Verified 9 days ago
| Provider Name | Kellie M Jones |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1790185999 PECOS PAC ID: 0042528366 Enrollment ID: I20151006000566 |
News Archive
China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic," or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), today announced that on September 2, 2009, the PRC's State Food and Drug Administration (the "SFDA") renewed SFDA certification of compliance with Good Manufacturing Practices ("GMP") for the production facility of Qianfeng Biological Products Co., Ltd. ("Qianfeng"), China Biologic's indirectly owned subsidiary.
The flu vaccine may not only ward off serious complications from influenza, it may also reduce the risk of heart attack or stroke by more than 50 per cent among those who have had a heart attack, according to new research led by Dr. Jacob Udell, a cardiologist at Women's College Hospital and clinician-scientist at the University of Toronto. What's more, the vaccine's heart protective effects may be even greater among those who receive a more potent vaccine.
Elusys Therapeutics, Inc., a privately-held biopharmaceutical company, announced today that it has been awarded a second contract year of funding valued at $40.6 million for the advanced development of Anthim for the prevention and treatment of anthrax infection following a biowarfare attack. This funding is in addition to $16.8 million already received under this contract and is part of a potential five year contract award totaling up to $143 million if all options are exercised by the Government.
A three-day conference exploring ways to increase access to family planning services in Africa kicked off in Nairobi, Kenya, on Tuesday, Capital FM reports. The meeting, which is hosted by USAID, will bring together "USAID's partners in sub-Saharan Africa who include Angola, Burundi, [Democratic Republic of Congo], Ethiopia, Guinea, Kenya, Nigeria, South Sudan and Tanzania," to work to identify gaps in reproductive and family planning services and address ways to reach out to populations in need, the news service writes (Karong'o, 5/11).
› Verified 9 days ago
| Provider Name | Ty H Smith |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1992282529 PECOS PAC ID: 7911241773 Enrollment ID: I20181205000242 |
News Archive
China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic," or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), today announced that on September 2, 2009, the PRC's State Food and Drug Administration (the "SFDA") renewed SFDA certification of compliance with Good Manufacturing Practices ("GMP") for the production facility of Qianfeng Biological Products Co., Ltd. ("Qianfeng"), China Biologic's indirectly owned subsidiary.
The flu vaccine may not only ward off serious complications from influenza, it may also reduce the risk of heart attack or stroke by more than 50 per cent among those who have had a heart attack, according to new research led by Dr. Jacob Udell, a cardiologist at Women's College Hospital and clinician-scientist at the University of Toronto. What's more, the vaccine's heart protective effects may be even greater among those who receive a more potent vaccine.
Elusys Therapeutics, Inc., a privately-held biopharmaceutical company, announced today that it has been awarded a second contract year of funding valued at $40.6 million for the advanced development of Anthim for the prevention and treatment of anthrax infection following a biowarfare attack. This funding is in addition to $16.8 million already received under this contract and is part of a potential five year contract award totaling up to $143 million if all options are exercised by the Government.
A three-day conference exploring ways to increase access to family planning services in Africa kicked off in Nairobi, Kenya, on Tuesday, Capital FM reports. The meeting, which is hosted by USAID, will bring together "USAID's partners in sub-Saharan Africa who include Angola, Burundi, [Democratic Republic of Congo], Ethiopia, Guinea, Kenya, Nigeria, South Sudan and Tanzania," to work to identify gaps in reproductive and family planning services and address ways to reach out to populations in need, the news service writes (Karong'o, 5/11).
› Verified 9 days ago
| Provider Name | Christina Marie Brown |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1700918729 PECOS PAC ID: 4789754656 Enrollment ID: I20231009000174 |
News Archive
China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic," or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), today announced that on September 2, 2009, the PRC's State Food and Drug Administration (the "SFDA") renewed SFDA certification of compliance with Good Manufacturing Practices ("GMP") for the production facility of Qianfeng Biological Products Co., Ltd. ("Qianfeng"), China Biologic's indirectly owned subsidiary.
The flu vaccine may not only ward off serious complications from influenza, it may also reduce the risk of heart attack or stroke by more than 50 per cent among those who have had a heart attack, according to new research led by Dr. Jacob Udell, a cardiologist at Women's College Hospital and clinician-scientist at the University of Toronto. What's more, the vaccine's heart protective effects may be even greater among those who receive a more potent vaccine.
Elusys Therapeutics, Inc., a privately-held biopharmaceutical company, announced today that it has been awarded a second contract year of funding valued at $40.6 million for the advanced development of Anthim for the prevention and treatment of anthrax infection following a biowarfare attack. This funding is in addition to $16.8 million already received under this contract and is part of a potential five year contract award totaling up to $143 million if all options are exercised by the Government.
A three-day conference exploring ways to increase access to family planning services in Africa kicked off in Nairobi, Kenya, on Tuesday, Capital FM reports. The meeting, which is hosted by USAID, will bring together "USAID's partners in sub-Saharan Africa who include Angola, Burundi, [Democratic Republic of Congo], Ethiopia, Guinea, Kenya, Nigeria, South Sudan and Tanzania," to work to identify gaps in reproductive and family planning services and address ways to reach out to populations in need, the news service writes (Karong'o, 5/11).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Byhalia Vision Center Llc 1890 Goodman Rd E Ste 100, Southaven, MS 38671-9504 Ph: (662) 772-5882 | Byhalia Vision Center Llc 8250 Hwy 178 West, Byhalia, MS 38611-6776 Ph: (662) 850-1051 |
News Archive
China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic," or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), today announced that on September 2, 2009, the PRC's State Food and Drug Administration (the "SFDA") renewed SFDA certification of compliance with Good Manufacturing Practices ("GMP") for the production facility of Qianfeng Biological Products Co., Ltd. ("Qianfeng"), China Biologic's indirectly owned subsidiary.
The flu vaccine may not only ward off serious complications from influenza, it may also reduce the risk of heart attack or stroke by more than 50 per cent among those who have had a heart attack, according to new research led by Dr. Jacob Udell, a cardiologist at Women's College Hospital and clinician-scientist at the University of Toronto. What's more, the vaccine's heart protective effects may be even greater among those who receive a more potent vaccine.
Elusys Therapeutics, Inc., a privately-held biopharmaceutical company, announced today that it has been awarded a second contract year of funding valued at $40.6 million for the advanced development of Anthim for the prevention and treatment of anthrax infection following a biowarfare attack. This funding is in addition to $16.8 million already received under this contract and is part of a potential five year contract award totaling up to $143 million if all options are exercised by the Government.
A three-day conference exploring ways to increase access to family planning services in Africa kicked off in Nairobi, Kenya, on Tuesday, Capital FM reports. The meeting, which is hosted by USAID, will bring together "USAID's partners in sub-Saharan Africa who include Angola, Burundi, [Democratic Republic of Congo], Ethiopia, Guinea, Kenya, Nigeria, South Sudan and Tanzania," to work to identify gaps in reproductive and family planning services and address ways to reach out to populations in need, the news service writes (Karong'o, 5/11).
› Verified 9 days ago